Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients

Journal of the American Society of Nephrology

Volumn 9, Issue 8, 1998, Pages 1521-1525

  Broeders, Nilüfer ^a   Wissing, K Martin ^a   Crusiaux, Alain ^a   Kinnaert, Paul ^a   Vereerstraeten, Pierre ^a   Abramowicz, Daniel ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3;

ADULT; ANTIBODY RESPONSE; ARTICLE; FEMALE; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031927585     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Norman DJ, Kahana L, Stuart FP, Thistlethwaite JR, Shield CF III, Monaco A, Dehlinger J, Wu S, Van Horn A, Haverty TP: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55: 44-50, 1993
2. Opelz G: Collaborative Transplant Study: Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 60: 1220-1224, 1995
3. Abramowicz D, Norman DJ, Vereerstraeten P, Goldman M, De Pauw L, Vanherweghem JL, Kinnaert P, Kahana L, Stuart FP, Thistlethwaite JR, Shield CF III, Monaco A, Wu S, Haverty TP: OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival. Kidney Int 49: 768-772, 1996
4. Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337-342, 1985
5. Norman DJ, Barry JM, Bennett WM, Leone M, Henell KR, Funnell B, Hubert B: The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 11: 90-93, 1988
6. DeMattos AM, Norman DJ: OKT3 for treatment of rejection in renal transplantation. Clin Transplant 7: 374-381, 1993
7. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF: Restriction of the human in vivo immune response against the mouse mAb OKT3. J Immunol 137: 830-838, 1986
8. Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB: Monoclonal antibody therapy: Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41: 572-578, 1986
9. Norman DJ, Shield CF III, Henell KR, Kimball J, Barry JM, Bennett WM, Leone M: Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 46: 523-529, 1988
10. Mayes JT, Thistlethwaite JR, Stuart JK, Buckingham MR, Stuart FP: Reexposure to OKT3 in renal allograft recipients. Transplantation 45: 349-353, 1988
11. First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler JP, Ryckman FC, Brunson ME: Successful retreatment of allograft rejection with OKT3. Transplantation 47: 88-91, 1989
12. Legendre C, Kreis H, Bach JF, Chatenoud L: Prediction of successful allograft rejection retreatment with OKT3. Transplantation 53: 87-90, 1992
13. Chatenoud L: Immunologic monitoring during OKT3 therapy. Clin Transplant 7: 422-430, 1993
14. Shield CF III, Norman DJ, Marlett P, Fucello AJ, Goldstein G: Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin. Nephron 46: 48-51, 1987
15. Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, Melvin DB, Penn I, Balistreri WF, Alexander JW: Antimurine antibody formation following OKT3 therapy. Transplantation 49: 48-51, 1990
16. Hricik DE, Mayes JT, Schulak JA: Inhibition of anti-OKT3 antibody generation by cyclosporin: Results of a prospective randomized trial. Transplantation 50: 237-240, 1990
17. Chatenoud L, Bach JF: Therapeutic monoclonal antibodies in transplantation. Transplant Proc 25: 473-474, 1993
18. Muraguchi A, Butler JL, Kehrl JH, Falkoff RJM, Fauci AS: Selective suppression of an early step in human B cell activation by CsA. J Exp Med 158: 690-702, 1983
19. Klaus GGB: Cyclosporine-sensitive and cyclosporine-insensitive modes of B cell stimulation. Transplantation 46: 11S-14S, 1988
20. Wicker LS, Boltz RC, Matt V, Nichols EA, Peterson LB, Sigal NH: Suppression of B cell activation by CsA, FK506 and rapamycin. Eur J Immunol 20: 2277-2283, 1990
21. Bach JF, Strom TB: The Mode of Action of Immunosuppressive Agents: Research Monographs in Immunology, 2nd Ed., Vol. 9, Amsterdam, Elsevier, 1986, pp 105-158
22. Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Choc M, Wong R, Hwang DS: Reduced inter-and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 59: 505-511, 1995
23. Allison AC, Almquist SJ, Muller CD, Eugui EM: In vitro immunosuppressive effects of Mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 23: S10-S14, 1991
24. Eugui EM, Almquist SJ, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of Mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 33: 161-173, 1991
25. Goldstein G, Fuccello AJ, Norman DJ, Shield CF III, Colvin RB, Cosimi AB: OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42: 507-511, 1986
26. Bierer BE, Hollander G, Fruman D, Burakoff SJ: Cyclosporin A and FK506: Molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 5: 763-773, 1993
27. Hodge MR, Rooney JW, Glimcher LH: The proximal promoter of the IL-4 gene is composed of multiple essential regulatory sites that bind at least two distinct factors. J Immunol 154: 6397-6405, 1995
28. Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23: S15-S18, 1991
29. Azuma H, Binder J, Heeman UW, Schmid C, Tullius SG, Tilney NL: Effects of RS-61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 59: 460-466, 1995
30. Kimball J, Pescovitz MD, Book BK, Norman DJ: Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving Mycophenolate Mofetil. Transplantation 60: 1379-1383, 1995
31. Meredith RF, Khazaeli MB, Plott WE, Brezovich IA, Russel CD, Wheeler RH, Spencer SA, Lobuglio AF: Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer. Antibodies, Immunoconjugates and Radiopharmaceuticals 5: 75-80, 1992
32. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340: 748-752, 1992
33. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125-1127, 1994
34. Lederer SR, Schneeberger H, Albert E, Johnson JP, Gruber R, Land W, Burkhardt K, Hillebrand G, Feucht H: Early renal graft dysfunction: The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation 61: 313-319, 1996
35. Feucht HE, Opelz G: The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 50: 1464-1475, 1996
36. Abe M, Kawai T, Futatsuyama K, Tanabe K, Fuchinoue S, Teraoka S, Toma H, Ota K: Postoperative production of antidonor antibody and chronic rejection in renal transplantation. Transplantation 63: 1616-1619, 1997
37. Costa AN, Scolari MP, Iannelli S, Buscaroli A, D'Arcangelo GL, Brando B, Indiveri F, Savi M, Borgnino LC, DeSanctis LB, Stefoni S, Bonomini V: The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 63: 167-169, 1997